Reported a net loss of $3.5 million for the first quarter of 2026, compared to a $2.6 million loss in the same period of 2025. Operating expenses increased to $3.5 million, driven by higher R&D spending on the EB613 and OPKO collaboration programs. Cash and cash equivalents were $4.1 million as of March 31, 2026, with an additional $7.8 million in restricted cash. Completed a $10 million private placement in April 2026 to fund the upcoming Phase 3 registrational study for EB613. Management believes current cash resources are sufficient to support operations through the first quarter of 2027.